MRK vs SNY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Sanofi presents a mixed profile characterized by a stable Piotroski F-Score of 4/9 and a very conservative debt-to-equity ratio of 0.28. While the stock trades near its Graham Number ($43.22), it is significantly above its growth-based intrinsic value ($16.66), suggesting a valuation premium. The most critical concern is the unsustainable dividend payout ratio of 96.04%, which threatens the long-term viability of the 5.04% yield. Despite a bearish technical trend (0/100), the low forward P/E of 9.09 and positive analyst targets provide a counter-balance to the current stagnation.
Compare Another Pair
Related Comparisons
MRK vs SNY: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Sanofi (SNY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.